Unveiling the role of network and systems biology in drug discovery

Trends in Pharmacological Sciences

Volumn 31, Issue 3, 2010, Pages 115-123

  Pujol, Albert ^a,b   Mosca, Roberto ^a   Farrés, Judith ^b   Aloy, Patrick ^a,c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b Anaxomics Biotech   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIPROTOZOAL AGENT; CELECOXIB; CETUXIMAB; CLAVULANIC ACID; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FINASTERIDE; GEFITINIB; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ILOMASTAT; IMATINIB; INTERSTITIAL COLLAGENASE; NEUROLEPTIC AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; TAXANE DERIVATIVE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BREAST CANCER; CANCER GENETICS; CARDIOVASCULAR DISEASE; DRUG INDUSTRY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INSOMNIA; LUNG METASTASIS; MATHEMATICAL MODEL; MENTAL DISEASE; METASTASIS INHIBITION; NAUSEA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

DRUG DISCOVERY; METABOLIC NETWORKS AND PATHWAYS; SYSTEMS BIOLOGY;

EID: 77649182705     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.11.006     Document Type: Review

References (96)

1. Butcher E.C. Can cell systems biology rescue drug discovery?. Nat. Rev. Drug Discov. 4 (2005) 461-467
2. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
3. Rual J.F., et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437 (2005) 1173-1178
4. Stelzl U., et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122 (2005) 957-968
5. Ewing R.M., et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3 (2007) 89
6. Barrett T., et al. NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res. 35 (2007) D760-765
7. Parkinson H., et al. ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res 35 (2007) D747-750
8. Pearson H. Meet the human metabolome. Nature 446 (2007) 8
9. Wishart D.S., et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 35 (2007) D521-526
10. Drews J. Case histories, magic bullets and the state of drug discovery. Nat. Rev. Drug Discov. 5 (2006) 635-640
11. Lindsay M.A. Finding new drug targets in the 21st century. Drug Discov. Today 10 (2005) 1683-1687
12. van der Greef J., and McBurney R.N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4 (2005) 961-967
13. Russell R.B., and Aloy P. Targeting and tinkering with interaction networks. Nat. Chem. Biol. 4 (2008) 666-673
14. Venkatesan K., et al. An empirical framework for binary interactome mapping. Nat. Methods 6 (2009) 83-90
15. Mani K.M., et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol. Syst. Biol. 4 (2008) 169
16. Pujana M.A., et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 39 (2007) 1338-1349
17. Amit I., et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 326 (2009) 257-263
18. Chuang H.Y., et al. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 3 (2007) 140
19. Chen Y., et al. Variations in DNA elucidate molecular networks that cause disease. Nature 452 (2008) 429-435
20. Kitano H. International alliances for quantitative modeling in systems biology. Mol. Syst. Biol. 1 (2005) 0007
21. Ro D.K., et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440 (2006) 940-943
22. Bonneau R., et al. A predictive model for transcriptional control of physiology in a free living cell. Cell 131 (2007) 1354-1365
23. Stuart L.M., et al. A systems biology analysis of the Drosophila phagosome. Nature 445 (2007) 95-101
24. Abbott A. Pharmaceutical futures: a fiendish puzzle. Nature 455 (2008) 1164-1167
25. Bar-Yan Y. Making Things Work: Solving Complex Problems in a Complex World (2004), NECSI Knowledge Press
26. Scriver C.R., and Waters P.J. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 15 (1999) 267-272
27. Dipple K.M., and McCabe E.R. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol. Genet. Metab. 71 (2000) 43-50
28. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
29. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
30. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
31. Jones D. Pathways to cancer therapy. Nat. Rev. Drug Discov. 7 (2008) 875-876
32. Pache R.A., et al. Towards a molecular characterisation of pathological pathways. FEBS Lett. 582 (2008) 1259-1265
33. Kitano H. Biological robustness. Nat. Rev. Genet 5 (2004) 826-837
34. Zanzoni A., et al. A network medicine approach to human disease. FEBS Lett. 583 (2009) 1759-1765
35. Xu J.J., et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105 (2008) 97-105
36. Jia J., et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8 (2009) 111-128
37. Gupta G.P., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446 (2007) 765-770
38. Takabatake D., et al. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int. J. Cancer 120 (2007) 181-188
39. Matsuura M., et al. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains. Antimicrob. Agents Chemother. 17 (1980) 908-911
40. Johnson M.D., et al. Combination antifungal therapy. Antimicrob. Agents Chemother. 48 (2004) 693-715
41. Zimmermann G.R., et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12 (2007) 34-42
42. Lehar J., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27 (2009) 659-666
43. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (2008) 682-690
44. Schrattenholz A., and Soskić V. What does systems biology mean for drug development?. Curr. Med. Chem. 15 (2008) 1520-1528
45. Giles F.J., et al. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia (2009)
46. Yildirim M.A., et al. Drug-target network. Nat. Biotechnol. 25 (2007) 1119-1126
47. Paolini G.V., et al. Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006) 805-815
48. Gregori-Puigjané E., and Mestres J. A ligand-based approach to mining the chemogenomic space of drugs. Comb. Chem. High Throughput Screen. 11 (2008) 669-676
49. Nacher J.C., and Schwartz J.-M. A global view of drug-therapy interactions. BMC Pharmacol. 8 (2008) 5
50. Roth B.L., et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004) 353-359
51. Bolognesi M.L., et al. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 6 (2009) 152-162
52. Apsel B., et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4 (2008) 691-699
53. Rasko D.A., et al. Targeting QseC signaling and virulence for antibiotic development. Science 321 (2008) 1078-1080
54. Todorovska A., et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248 (2001) 47-66
55. Kitano H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6 (2007) 202-210
56. Choong N.W., et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest. New Drugs (2009) Aug, 4. Ahead of print
57. Peterson J.J., and Novick S.J. Nonlinear blending: a useful general concept for the assessment of combination drug synergy. J. Recept. Signal Transduct. Res. 27 (2007) 125-146
58. Henney A., and Superti-Furga G. A network solution. Nature 455 (2008) 730-731
59. Saez-Rodriguez J., et al. Flexible informatics for linking experimental data to mathematical models via DataRail. Bioinformatics 24 (2008) 840-847
60. Apic G., et al. Illuminating drug discovery with biological pathways. FEBS Lett. 579 (2005) 1872-1877
61. Boguski M.S., et al. Drug discovery. Repurposing with a difference. Science 324 (2009) 1394-1395
62. Cleach L.L., et al. Reactions and interactions of some commonly used systemic drugs in dermatology. Dermatol. Clin. 16 (1998) 421-429
63. Ekman P. Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy. Scand. J. Urol. Nephrol. Suppl. 203 (1999) 15-20
64. O'Connor K.A., and Roth B.L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4 (2005) 1005-1014
65. Lee M.S., et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 67 (2007) 11359-11367
66. Charbonnier S., et al. The social network of a cell: recent advances in interactome mapping. Biotechnol. Annu. Rev. 14 (2008) 1-28
67. Lehar J., et al. Combination chemical genetics. Nat. Chem. Biol. 4 (2008) 674-681
68. Royer L., et al. Unraveling protein networks with power graph analysis. PLoS Comput. Biol. 4 (2008) e1000108
69. Missiuro P.V., et al. Information flow analysis of interactome networks. PLoS Comput. Biol. 5 (2009) e1000350
70. Friedman N. Inferring cellular networks using probabilistic graphical models. Science 303 (2004) 799-805
71. Sachs K., et al. Causal protein-signaling networks derived from multiparameter single-cell data. Science 308 (2005) 523-529
72. Jansen R., et al. A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science 302 (2003) 449-453
73. Llewellyn R., and Eisenberg D.S. Annotating proteins with generalized functional linkages. Proc. Natl. Acad. Sci. U S A 105 (2008) 17700-17705
74. Lahdesmaki H., et al. Relationships between probabilistic Boolean networks and dynamic Bayesian networks as models of gene regulatory networks. Signal Processing 86 (2006) 814-834
75. Kelley R., and Ideker T. Systematic interpretation of genetic interactions using protein networks. Nat. Biotechnol. 23 (2005) 561-566
76. Zhu J., et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet. 40 (2008) 854-861
77. Klamt S., et al. Hypergraphs and cellular networks. PLoS Comput. Biol. 5 (2009) e1000385
78. Barabasi A.L., and Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5 (2004) 101-113
79. Hartwell L.H., et al. From molecular to modular cell biology. Nature 402 (1999) C47-52
80. Ravasz E., et al. Hierarchical organization of modularity in metabolic networks. Science 297 (2002) 1551-1555
81. Gavin A.C., et al. Proteome survey reveals modularity of the yeast cell machinery. Nature 440 (2006) 631-636
82. Shen-Orr S.S., et al. Network motifs in the transcriptional regulation network of Escherichia coli. Nat. Genet. 31 (2002) 64-68
83. Milo R., et al. Network motifs: simple building blocks of complex networks. Science 298 (2002) 824-827
84. Kelley B.P., et al. PathBLAST: a tool for alignment of protein interaction networks. Nucleic Acids Res. 32 (2004) W83-88
85. Kalaev M., et al. NetworkBLAST: comparative analysis of protein networks. Bioinformatics 24 (2008) 594-596
86. Singh R., et al. Global alignment of multiple protein interaction networks with application to functional orthology detection. Proc. Natl. Acad. Sci. U S A 105 (2008) 12763-12768
87. Suthram S., et al. The Plasmodium protein network diverges from those of other eukaryotes. Nature 438 (2005) 108-112
88. Cookson W., et al. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 10 (2009) 184-194
89. Kumar C., and Mann M. Bioinformatics analysis of mass spectrometry-based proteomics data sets. FEBS Lett. 583 (2009) 1703-1712
90. Gstaiger M., and Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat. Rev. Genet. 10 (2009) 617-627
91. Boozer C., et al. Looking towards label-free biomolecular interaction analysis in a high-throughput format: a review of new surface plasmon resonance technologies. Curr. Opin. Biotechnol. 17 (2006) 400-405
92. Nedelkov D. Development of surface plasmon resonance mass spectrometry array platform. Anal. Chem. 79 (2007) 5987-5990
93. Sudhaharan T., et al. Determination of in vivo dissociation constant, KD, of Cdc42-effector complexes in live mammalian cells using single wavelength fluorescence cross-correlation spectroscopy. J. Biol. Chem. 284 (2009) 13602-13609
94. Simonetta M., et al. The influence of catalysis on mad2 activation dynamics. PLoS Biol. 7 (2009) e10
95. Iwahara J., et al. NMR structural and kinetic characterization of a homeodomain diffusing and hopping on nonspecific DNA. Proc. Natl. Acad. Sci. U S A 103 (2006) 15062-15067
96. Sprangers R., and Kay L.E. Quantitative dynamics and binding studies of the 20S proteasome by NMR. Nature 445 (2007) 618-622